Pembrolizumab plus axitinib showed superior overall survival and progression-free survival compared to sunitinib in advanced clear cell renal cell carcinoma. The combination therapy demonstrated a ...
"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this ...
Jonathan Rubenstein, MD, and Mark Painter answer a question regarding coding for use of the second-generation Calyxo CVAC system. Regarding your recent article, “Reporting use of ureter access sheath ...
Apalutamide shows a 23% reduction in mortality risk at 24 months compared to enzalutamide in mCSPC patients. The study's findings are consistent with the TITAN trial, confirming apalutamide's survival ...
In this episode, host Adam B. Weiner, MD, is joined by Maarten Albersen, MD, PhD, for a focused discussion on the evolving molecular landscape of penile cancer. The FDA Oncologic Drugs Advisory ...
Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US. The first US commercial surgical case using the Hugo robot-assisted ...
VIR-5500 demonstrated promising PSA response in mCRPC patients, with 58% achieving at least a 50% reduction in PSA levels. No dose-limiting toxicities were observed, and treatment-emergent adverse ...
Postoperative urinary retention is a common outcome after surgical procedures for pelvic organ prolapse and stress urinary incontinence. This clinical consensus statement on the management of ...
The FDA requires labeling changes for testosterone products due to findings from ABPM studies about increased blood pressure. TRAVERSE trial results will be added to all testosterone product labels, ...
"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...
Mitomycin for intravesical solution is the first FDA-approved treatment for recurrent LG-IR-NMIBC, with availability expected by July 2025. The phase 3 ENVISION trial demonstrated a 78% complete ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results